3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone has been researched along with Liver Neoplasms in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arber, N; Birkenfeld, S; Bulvik, B; Dvory-Sobol, H; Kazanov, D; Leshno, M; Liberman, E; Luk, P | 1 |
1 other study(ies) available for 3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5h)-furanone and Liver Neoplasms
Article | Year |
---|---|
MF tricyclic and sulindac retard tumor formation in an animal model.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Chemoprevention; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Furans; Injections, Subcutaneous; Liver Neoplasms; Mice; Mice, Nude; Placebos; Random Allocation; Single-Blind Method; Sulindac | 2006 |